Sequential treatment with lamivudine and interferon-α monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1031-1035

  Shi, Ming ^a,b   Wang, Rong Sheng ^c   Zhang, Hua ^c   Zhu, Yu Fen ^c   Han, Bei ^c   Zhang, Yong ^b   Jin, Li Ji ^a   Yang, Zhi Jun ^d   Xu, Yong Ping ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b Central Laboratory   (China)

^c Jiangsu Oil Field Hospital   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; HBV; Hepatitis B virus; YMDD

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; GENETICS; HEPATITIS B; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIVIRAL AGENTS; CHINA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 39049185195     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl385     Document Type: Article

References (33)

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Beasley RP. Hepatitis B virus: The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
3. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1: 232-41.
4. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
5. Averett DR, Masson WS. Evaluation of drugs for antiviral activity against hepatitis B virus. Viral Hepat Rev 1995; 1: 129-42.
6. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
7. Lok AS, Chung HT, Liu VW et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8.
8. Lok AS, Lai CL, Wu PC et al. Treatment of chronic hepatitis B with interferon: Experience in Asian patients. Semin Liver Dis 1989; 9: 249-53.
9. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
10. Terrault N, Ma M. Adding to the hepatitis B virus treatment arsenal: α-glucosidase inhibitor derivatives. Hepatology 2001; 33: 1544-6.
11. Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
12. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
13. Honkoop P, Niesters HG, de Man RA et al. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 1997; 26: 1393-5.
14. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
15. Mutimer D, Naoumov N, Honkoop P et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study. J Hepatol 1998; 28: 923-9.
16. Barbaro G, Zechini F, Pellicelli AM et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J hepatol 2001; 35: 406-11.
17. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-8.
18. Jaboli MF, Fabbri C, Liva S et al. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. World J Gastroenterol 2003; 9: 1491-5.
19. Tatulli I, Francavilla R, Rizzo GL et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35: 805-10.
20. Santantonio T, Niro GA, Sinisi E et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: A controlled pilot study. J Hepatol 2002; 36: 799-804.
21. Serfaty L, Thabut D, Zoulim F et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study. Hepatology 2001; 34: 573-7.
22. Schiefke I, Klecker C, Maier M et al. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int 2004; 24: 98-104.
23. Wang RS, Zhang H, Zhu YF et al. Detection of YMDD mutants using universal template real-time PCR. World J Gastroenterol 2006; 12: 1308-11.
24. Lok AS, Lai CL, Wu PC et al. Alpha-interferon treatment in Chinese patients with chronic hepatitis B. J Hepatol 1990; 11 Suppl 2: 121-5.
25. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75.
26. Lai CL, Dienstag J, Sshiff E. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
27. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
28. Marrone A, Zampino R, Portella G et al. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. J Viral Hepat 2005; 12: 186-91.
29. Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
30. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
31. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
32. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
33. Hu KQ. A practical approach to management of chronic hepatitis B. Int J Med Sci 2005; 2: 17-23.